Merck opens production facility exclusively for meglumine in Spain
The only facility in Europe solely dedicated to meglumine production
Merck announced the opening of a facility in Mollet des Vallès, Spain dedicated to the manufacture of meglumine, an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media.
The facility, validated by the FDA, is the only location in Europe that manufactures meglumine, an amino sugar derived from glucose. The facility in Spain is solely dedicated to the production of meglumine, thereby ensuring continuity of supply to customers as well as meeting increasing demand for the excipient. As an excipient, meglumine interacts directly with active pharmaceutical ingredients to increase solubility. Therefore, the manufacture of meglumine must meet the same stringent regulatory and quality requirements as APIs.
“Our new facility was optimized around the manufacturing process to achieve greater efficiencies and meets the most stringent quality standards for manufacturing meglumine,” said Andrew Bulpin, Head of Process Solutions Strategic Marketing & Innovation, Life Science. “The result is a high level of confidence in quality and security of supply for our customers.”
Other news from the department business & finance
These products might interest you
KNAUER IJM NanoScaler by KNAUER
Efficient formulation of lipid nanoparticles for RNA-based therapies
Optimise drug encapsulation from 1 ml to hundreds of millilitres with minimal drug input
Pharmaceutical Substances by Thieme Verlag
Look up Industrial Syntheses of 2,600 APIs
Your tool for Syntheses, Patents and Applications – Pharmaceutical Substances
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
